Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
Effects of Treatment With Botulinum Toxin Type A on Clinical and Biophysical Parameters in Patients With Erythematotelangiectatic Rosacea
TAKE-HOME MESSAGE
- In this randomized, double-blind, split-face study, 30 patients with erythematotelangiectatic rosacea underwent treatment with 5 units of intradermal botulinum toxin A (BoNT-A) on one side of the face and saline on the other side. The sides treated with BoNT-A showed significantly reduced Clinician's Erythema Assessment scores, erythema index, and dermatoscopic background erythema compared with baseline, whereas no significant changes were noted on the saline control sides. In addition, the rate of good response to treatment, measured using the Investigator Global Assessment Scale, was significantly higher for the BoNT-A–treated sides than for the saline-treated sides.
- In this study, intradermal BoNT-A treatment significantly reduced erythema and vascular density in patients with erythematotelangiectatic rosacea.
abstract
This abstract is available on the publisher's site.
Access this abstract nowBACKGROUND
Erythematotelangiectatic rosacea (ETR) lacks a gold-standard treatment. Recent studies show that intradermal Botulinum Toxin-A (BoNT-A) is effective for erythema, though objective data are limited.
OBJECTIVE
This study aims to evaluate the efficacy and tolerability of intradermal BoNT-A in patients with ETR.
METHODS
In this randomized, double-blind, split-face study, 30 patients were enrolled. One side of the face received 15 units of BoNT-A, reconstituted in 10 mL of saline, while the control side received saline injections. Assessments were made at baseline and 1-month posttreatment. Clinician's Erythema Assessment (CEA) scale and Patient Self-Assessment (PSA) scores were recorded. Erythema and Melanin Index measurements using a Mexameter. Background erythema was assessed through dermatoscopy, while vascular structure and density were evaluated using Investigative Global Assessment (IGA) scores through videocapillaroscopy.
RESULTS
The BoNT-A-treated side demonstrated significant reductions in CEA scores, Erythema Index, and dermatoscopic background erythema, while no significant changes were observed on the saline control side. IGA scores indicated a significant response to treatment on the BoNT-A side. Patient Self-Assessment scores improved on both sides. No serious adverse events requiring hospitalization were reported.
CONCLUSION
Intradermal BoNT-A effectively reduces erythema and vascular density in patients with ETR and is well-tolerated.
Additional Info
Effects of Botulinum Toxin Type A Treatment on Clinical and Biophysical Parameters in Patients With Erythematotelangiectatic Rosacea: A Prospective, Randomized, Controlled, Double-Blind Study
Dermatol Surg 2024 Dec 16;[EPub Ahead of Print], BB Dağtaş, O Erdem, Tİ Güneç, EB Avcı, V Manav, AE Koku AksuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.